Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of methyl ferulic acid in preparation of medicine for preventing and curing hepatic fibrosis

A technology of methyl ferulic acid and liver fibrosis, applied in the field of medicine, can solve problems such as unseen liver fibrosis diseases

Inactive Publication Date: 2014-08-13
GUILIN MEDICAL UNIVERSITY
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Existing reports indicate that Cicada has strong anti-bacterial, anti-inflammatory, anti-cancer, anti-virus, anti-HIV, immune enhancement and other activities, but so far no use of methyl ferulic acid extracted from Cicada has been seen. Related reports on the treatment of liver fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of methyl ferulic acid in preparation of medicine for preventing and curing hepatic fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0011] Example 1 Inhibitory effect of methyl ferulic acid on the proliferation and collagen synthesis of rat fat storage cell line HSC-T6 cells:

[0012] HSC-T6 cells were cultured in DMEM medium with 10% fetal bovine serum. Cells in the logarithmic growth phase were taken, and the cell concentration was adjusted to 1×10 5 / ml, 100μl per well, inoculated in 96-well cell culture plate. 5% CO at 37°C 2 Cultivate in the incubator for 24 hours, remove the medium, and incubate with the medium containing different concentrations of drugs (the final concentration of methyl ferulic acid is 2.5 μg / ml, 5 μg / ml, 10 μg / ml, 20 μg / ml, 40 μg / ml) For 24 hours, set up a blank control group at the same time, set 5 duplicate wells for each sample, then add 20ul of MTT (5mg / ml) to each well and continue to incubate for 4h, pour out the medium, blot dry, add 200ul of dimethyl sulfoxide to each well After mixing, set an automatic microplate reader (detection wavelength 490nm) to read the opt...

Embodiment 2

[0016] Example 2 Methyl ferulic acid to CCl 4 And the test of the impact of D-Gal on the acute liver injury animal model:

[0017] 1. Drugs and animals

[0018] 1.1 Animals 110 Kunming mice, half male and half male, weighing 22±2g.

[0019] 1.2 Grouping of animals: Randomly divide the animals into 11 groups, 10 animals in each group.

[0020] The first group is the normal animal control group, and the other groups are the model groups. Among them, groups 2, 3, 4, 5, and 6 use CCL 4 Modeling, i.e. using CCl 4 Induced acute liver injury in mice; while the 7th, 8th, 9th, 10th, and 11th models were made with D-Gal, that is, D-Gal was used to induce acute liver injury in mice.

[0021] 1.3 Therapeutic drugs

[0022] (1) Bifendate, which is a traditional liver-protecting drug, is a drug approved by SFDA for marketing, and is used as a positive control drug.

[0023] (2) Methyl ferulic acid is an experimental drug to observe its protective effect on acute liver inju...

Embodiment approach

[0025] 2.1 Dose setting

[0026] Group 1 is normal control group, group 2 is CCL 4 Model control group, the seventh group is the D-Gal model control group. Groups 1, 2, and 7 were gavaged with vehicle at a dose of 10ml / kg;

[0027] The 3rd, 8th groups are the bifendate treatment group, dosage is 200mg / kg, as the positive control group of the methyl ferulic acid treatment group;

[0028] The 4th, 5th, 6th groups and the 9th, 10th, 11th groups were the treatment groups of low, medium and high doses of methyl ferulic acid respectively, and the doses were 50mg / kg, 100mg / kg, 200mg / kg respectively.

[0029] 2.2 Administration method

[0030] The above-mentioned groups were administered intragastrically for 2 days according to the dose, once a day. On day 3, groups 2, 3, 4, 5, and 6 were treated with 0.5% CCL 4 - Peanut oil is injected intraperitoneally once at a dose of 10ml / kg to create acute CCL 4 Liver injury model: Groups 7, 8, 9, 10, and 11 were intraperitoneally ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the application of methyl ferulic acid in the preparation of drugs for the prevention and treatment of liver fibrosis. According to the in vitro cell model, it is confirmed that methyl ferulic acid has the effect on the proliferation of rat primary hepatic stellate cells (HSC) and the synthesis of collagen. Obvious inhibitory effect; animal experiments show that methyl ferulic acid has a protective effect on acute liver injury caused by carbon tetrachloride (CCl4) and D-galactosamine (D-Gal) in mice, and can prevent the occurrence of liver fibrosis ; The rat model of chemical liver fibrosis caused by CCL4 and the rat model of immune liver fibrosis caused by bovine serum albumin have confirmed that methyl ferulic acid has a good therapeutic effect on chronic liver fibrosis, and can be used alone or The compound recipe is used to prepare medicines for preventing and treating liver fibrosis.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the application of methyl ferulic acid in the preparation of drugs for preventing and treating liver fibrosis. Background technique [0002] Hepatic fibrosis (HF) refers to a pathological change in liver structure and function caused by excessive proliferation and abnormal deposition of extracellular matrix in liver tissue. Almost all chronic liver diseases, including chronic hepatitis B (C) virus, chronic alcoholic and autoimmune liver diseases, etc., experience this pathological process, and with the further development of liver fibrosis, liver cirrhosis will be formed, seriously endangering For human health, it is of great significance to find effective drugs for the prevention and treatment of liver fibrosis. [0003] Securidaca inappendiculata Hassk is a climbing shrub of the genus Securidaca inappendiculata Hassk. Its rhizomes are pungent, sweet and bitter in taste, slig...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/192A61P1/16C07C59/64C07C51/42
Inventor 李勇文李丽李勇军容明智庞勇军黎荣程钰庞文箫
Owner GUILIN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com